exemestane
Aliases
Aromasin
6 clinical trials
2 products
25 abstracts
1 indication
Indication
Breast CancerAbstract
Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul National University Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Department of Hematology-Oncology,
Abstract
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors.Org: Gustave Roussy Cancer Center, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology, Clinical Oncology Department, IRCCS Ospedale Policlinico San Martino Genoa, Genova, Italy, IRCCS Ospedale Policlinico San Martino Genoa,
Abstract
Nationwide real-world practice pattern and clinical data of palbociclib in patients with HR(+), HER2(-) metastatic breast cancer (KCSG BR21-15).Org: Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital, Seoul, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Neoadjuvant dalpiciclib, exemestane, and goserelin in premenopausal women with HR-positive, HER2-negative breast cancer: A prospective, multicenter, randomized two-group, non-controlled phase 2 clinical trial.Org: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Hemay Pharmaceutical, China National Biotec Group, Tianjian,
Abstract
Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2− recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor.Org: Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan, Tohoku University Hospital, Miyagi, Japan, National Center for Global Health and Medicine, Tokyo, Japan, NHO Shikoku Cancer Center, Ehime, Japan, Showa University, Tokyo, Japan,
Abstract
International phase 3 clinical trial evaluating PF-07220060 plus fulvestrant in patients with HR+/HER2− advanced/metastatic breast cancer with progression after a prior CDK4/6 inhibitor.Org: Dana-Farber Cancer Institute, Institut Jules Bordet, Université Libre de Bruxelles, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Centro de Pesquisa Clínica Hospital São Lucas da PUCRS,
Abstract
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: An overall survival update and long-term safety from the randomised, double-blind, placebo-controlled, phase 3 trial.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Harbin Medical University Cancer Hospital,
Abstract
Aromatase inhibitor musculoskeletal toxicity (AIMT) in patients (pts) with early breast cancer (EBC): Prevalence, management, and association with non-adherence to AI.Org: Cancer Survivorship Program, INSERM 981, Gustave Roussy, Villejuif, France, INSERM 981, Gustave Roussy Département d'Organisation du Parcours Patient, Villejuif, France, France,
Abstract
Linking the companion diagnostic function of cancer genome profiling to therapy: Investigation of TMB-high predictors.Org: Hiroshima Prefectural Hospital, Hiroshima City North Medical Center Asa Citizens Hospital, JA Onomichi General Hospital, JA Hiroshima General Hospital,
Abstract
Everolimus for advanced breast cancer: Is the histological subtype important?Org: Hospital Universitario Reina Sofía, Virgen Macarena University Hospital, Virgen de las Nieves Hospital, Jaen University Hospital,
Abstract
The impact of cannabidiol (CBD) on aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS).Org: University of Michigan Health Management Research Center,
Clinical trial
A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2011-03-11
Clinical trial
Effect of Aromatase Inhibitor Therapy for Breast Cancer on Endothelial FunctionStatus: Completed, Estimated PCD: 2013-06-13
Clinical trial
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2022-12-01
Clinical trial
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast CancerStatus: Completed, Estimated PCD: 2011-03-25
Clinical trial
A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast CancerStatus: Completed, Estimated PCD: 2010-11-07
Abstract
Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT trial.Org: University of Chicago, European Institute of Oncology, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Peter MacCallum Cancer Centre, Melbourne, Australia, International Breast Cancer Study Group,
Abstract
Evolving adjuvant estrogen therapy prescribing among breast oncology workforce.Org: University of Chicago, University of Chicago Medical Center, Chicago, IL, Section of Urology, Department of Surgery, Brigham and Women's Hospital, Boston, MA, University of Chicago Department of Urology,
Abstract
A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE).Org: Mayo Clinic, Rochester, MN, Phoenix, AZ, Jacksonville, FL, Clear Lake Oncology,
Abstract
evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).Org: Dana-Farber Cancer Institute, UPMC Hillman Cancer Center, University of Pittsburgh Cancer Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Memorial Sloan Kettering Cancer Center,
Abstract
Influence of ovarian function supression on quality of life in breast cancer survivors during adjuvant endocrine therapy.Org: School of Medicine University of Zagreb, Agency for Medicinal Products and Medical Devices of Croatia, University Hospital Centre Zagreb, General Hospital Sibenik, General Hospital Šibenik,
Abstract
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy.Org: The Ottawa Hospital Research Institute, McMaster University and Juravinski Cancer Centre, Ontario Institute for Cancer Research, Toronto, ON, Canada, Diagnostic Development, Toronto Allergy and Asthma Centre,
Abstract
ctDNA mutational profiles in luminal breast cancer with early vs late distant relapse: Geicam/2014-03.Org: Fundación Instituto Valenciano de Oncología (FIVO), GEICAM Spanish Breast Cancer Group, Valencia, Spain, GEICAM Spanish Breast Cancer Group, Barcelona, Spain, Hospital Universitario de Donostia-BioDonostia, Hospital de la Santa Creu i Sant Pau, Hospital Universitario de Canarias,
Abstract
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).Org: NSABP Foundation and UPMC Hillman Cancer Center, Pittsburgh, PA, Massachusetts General Hospital, Harvard Medical School, Boston, MA, Breast Center, Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany, Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX, University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Neoadjuvant stereotactic body radiotherapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer.Org: Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China,
Abstract
Longitudinal trends in serum calcium, parathormone and bone mineral density in breast cancer survivors on aromatase inhibitor therapy: A single institutional cohort study.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Cleveland Clinic Taussig Cancer Instititute, University of Pittsburgh Medical Center, Endocrinology and metabolic institute, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,
Abstract
Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR+ breast cancer in the TEAM trial.Org: Cancer Research UK Scotland Centre, University of Edinburgh Cancer Research UK Centre, Unity Health Toronto, Biotheranostics, A Hologic Company, A Hologic Company,
Abstract
Symptom burden of patients with breast cancer on adjuvant hormone therapy: A preliminary report.Org: Thomas Jefferson University, Sidney Kimmel Cancer Center at Thomas Jefferson University, Fox Chase Cancer Center,
Abstract
Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Shengjing Hospital of China Medical University, Department of Breast Surgery, Kyorin University School of Medicine/Saitama Medical Center, Tokyo, Japan, The First Affiliated Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China,
Abstract
Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity.Org: EHC, Morges, Switzerland, University Hospital 12 de Octubre, Institut Curie, Saint Cloud, France, Centre GF Leclercq,
Product
Adjuvant endocrine therapyClinical trial
A Prospective, Randomized, Open-label, Multicenter Study Evaluating the Effects on Cognitive Functions of Adjuvant Endocrine Therapy in Postmenopausal Women With Breast Cancer.Status: Completed, Estimated PCD: 2012-04-04